3 FORBES ROAD, LEXINGTON, MA
Material disclosure
Other Events
Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
Shareholder votes
Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Biologics Manufacturing in the US
Reports Q1 2025 Financial Results and Key Business Updates
Annual Report to Security Holders
Earnings Release
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Definitive Revised Proxy Statement
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement
Correspondence